M&A TRANSACTION · 2021
Symplr acquired by Charlesbank Capital
$3.40B· 17.9x EBITDA
Target
Symplr
Acquirer
Charlesbank Capital
Private Equity buyer
Disclosed financials at time of acquisition
Revenue
—
EBITDA
$190.0M
Deal Value
$3.40B
EV/EBITDA
17.9x
Context
This $3.40B acquisition of Symplr by Charlesbank Capital sits in the healthcare it sub-vertical. The 17.9x EBITDA multiple paid in 2021 can be compared against the population median for healthcare it transactions of similar size on our Healthcare It valuation hub. Charlesbank Capital is acquiring as a private equity buyer; see how PE acquirers typically price healthcare it businesses on our Healthcare It PE buyer-pool page.
Source
Data sourced from Press reporting. All figures reflect disclosed values at the time of the acquisition; no estimated or imputed data. Methodology
Value your own healthcare it
Get an instant valuation range for your business. Backed by 25,592 real M&A transactions.
Compare your business to the Symplr acquisition.